Menu Search
Equities

Joinn Laboratories China Co Ltd

603127:SHH

Joinn Laboratories China Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.65
  • Today's Change-0.37 / -2.64%
  • Shares traded10.62m
  • 1 Year change-41.24%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy2
Outperform4
Hold2
Sell1
Strong Sell0

Share price forecast in CNY

The 5 analysts offering 12 month price targets for Joinn Laboratories China Co Ltd have a median target of 13.28, with a high estimate of 19.50 and a low estimate of 6.90. The median estimate represents a -2.71% decrease from the last price of 13.65.
High42.9%19.50
Med-2.7%13.28
Low-49.5%6.90

Dividends in CNY

In 2023, Joinn Laboratories China Co Ltd reported a dividend of 0.16 CNY, which represents a 44.00% decrease from last year. The 3 analysts covering the company expect dividends of 0.11 CNY for the upcoming fiscal year, a decrease of 31.25%.
Div growth (TTM)-44.00%
More ▼

Earnings history & estimates in CNY

On Aug 30, 2024, Joinn Laboratories China Co Ltd reported 2nd quarter 2024 earnings of 0.13 per share.
The next earnings announcement is expected on Oct 29, 2024.
Average growth rate-71.56%
Joinn Laboratories China Co Ltd reported annual 2023 earnings of 0.529 per share on Mar 28, 2024.
Average growth rate+37.99%
More ▼

Revenue history & estimates in CNY

Joinn Laboratories China Co Ltd had 2nd quarter 2024 revenues of 524.55m. This missed the 609.13m estimate of the one analyst following the company. This was 42.01% above the prior year's 2nd quarter results.
Average growth rate+7.29%
Joinn Laboratories China Co Ltd had revenues for the full year 2023 of 2.38bn. This was 4.78% above the prior year's results.
Average growth rate+40.89%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.